[1] 中华人民共和国药典委员会.中华人民共和国药典临床用药须知[M].北京:中国医药科技出版社,2010:1442 Chinese Phamacopoiea Committee.ChP the Notice of Drugs in Clinical Use[M].Beijing:China Medical Science Press,2010:1442
[2] 殷为勇,郑荣远,朱振国,等.甲苯咪唑的研发、市场与临床应用[J].中国现代应用药学,2008,25(4):301 YIN WY,ZHENG RY,ZHU ZG,et al.Research marketing and clinical application of mebendazole[J].Chin J Mod Appl Pharm,2008,25(4):301
[3] 中华人民共和国药典2015年版.二部[S].2015:200 ChP 2015.VolⅡ[S].2015:200
[4] BP 2014[S].2014:Ⅱ-193
[5] EP 8.0[S].2014:2696
[6] USP 37[S].2014:3657
[7] IP 6[S].2016
[8] ALINE Q,PENNA G,TASSIA H,et al.Evaluation and study of mebendazole polymorphs present in raw materials and tablets available in the Brazilian pharmaceutical market[J].J App Pharm Sci,2014,4(11):001
[9] MARIUS B,WILNA L,MELGARDT M.Characterization of polymorph transformations that decrease the stability of tablets containing the WHO essential drug mebendazole[J].J Pharm Sci,2010,99(3):1138
[10] OLIMPIA M,MARIA E,JENNIFER T,et al.Polymorphism:an evaluation of the potential risk to the quality of drug products from the Farmácia Popular RedePrópria[J].Braz J Pharm Sci,2014,55(1):1
[11] 庞庆林,袁耀佐,张玫,等.国产利福平口服制剂质量评价[J].药物分析杂志,2011,31(10):1862 PANG QL,YUAN YZ,ZHANG M,et al.Assessment the quality of domestic rifampicin for oral preparation[J].Chin J Pharm Anal,2011,31(10):1862
[12] ERNA S,WILNA L,MELGARDT M.Quality evaluation of generic drugs by dissolution test:changing the USP dissolution medium to distinguish between active and non-active mebendazole polymorphs[J].Eur J Pharm Biopharm,2003,55(3):345
[13] SARA B,SILVIA F,ARNALDO V,et al.Polymorphism evaluation in generic tablets containing mebendazole by dissolution tests[J].Braz Chem Soc,2012,23(2):220
[14] 刘洁,刘辉.阿司匹林肠溶片质量研究与分析[J].药物分析杂志,2015,35(12):2187 LIU J,LIU H.Quality evaluation and analysis of domestic aspirin enteric-coated tablets[J].Chin J Pharm Anal,2015,35(12):2187
[15] NATALIA L,TEODORO S,RUBEN M.Mebendazole crystal forms in tablet formulations.An ATR-FTIR/chemometrics approach to polymorph assignment[J].J Pharm Biomed Anal,2016,122(1):157